<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1292">
  <stage>Registered</stage>
  <submitdate>11/09/2006</submitdate>
  <approvaldate>11/09/2006</approvaldate>
  <nctid>NCT00376402</nctid>
  <trial_identification>
    <studytitle>Study of a Pandemic Influenza Vaccine in Elderly Participants</studytitle>
    <scientifictitle>Phase II Study of a Pandemic Influenza Vaccine in Elderly Participants</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CSLCT-PAN-05-24</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - H5N1 Pandemic Influenza Vaccine

Other interventions: H5N1 Pandemic Influenza Vaccine


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and immunogenicity</outcome>
      <timepoint />
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy male and female participants</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History of clinically significant medical conditions

          -  History of Guillain-Barre syndrome or active neurological disease

          -  Resident of nursing home or long-term care facility</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,WA</recruitmentstate>
    <hospital>CMAX, a division of IDT Australia - Adelaide</hospital>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>6840 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Seqirus</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The World Health Organisation has warned that an influenza pandemic is inevitable. The avian
      influenza H5N1 virus strain is one of the leading candidates to cause the next influenza
      pandemic. The elderly are likely to be a special target group for vaccination; therefore,
      this study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in a
      healthy elderly population.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00376402</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Richmond, Dr</name>
      <address>Princess Margaret Hospital for Children</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>